Immune Checkpoint Inhibitor-Related Rash and Diabetes Mellitus in a Patient with Melanoma

Share your views on Insulin Therapy for Sudden Onset of Immune-Checkpoint Inhibitor Diabetes Mellitus Community of Doctors A man in his 40s with a history of BRAF-positive melanoma on his back presented with a 2-day history of a widespread urticarial rash. He had been treated with nivolumab/ipilimumab for melanoma and experienced a localized erythematous rash after the first dose of immunotherapy but had no rashes with subsequent doses. On examination, he had an erythematous maculopapular rash across his axillae, chest, back, face, and arms. He was obese, weighing 125.5kg. Laboratory investigations were performed. Given the sudden onset of hyperglycemia, the possibility of immune checkpoint inhibitor-associated diabetes mellitus was made (1). Quick options for you (click to select) : Which insulin therapy would you suggest for this patient? Metformin and insulin glargine Insulin aspart, insulin glargine, metformin, and Semaglutide Insulin lispro and Semaglutide Insulin delemir, metformin, and insulin glargine Suggest Treatment This email is intended for Dr. Renukaprasad A R Unsubscribe / Change your email preferences. © 2023 MedSynapse, USA, Singapore, India, Dubai